Hepatitis virus infections are common among injecting drug users.
Syringes containing hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA were identified by polymerase chain reaction (PCR) ; syringes containing antibodies to HBV core antigen and HCV were identified by EIA.
Syringe use was simulated to determine the sensitivity of these assays.
The mean limits for PCR were 0.082 muL of blood for HBV and 0.185 muL for HCV ; the mean limits for EIA were 0.185 muL for HBV and 0.023 muL for HCV.
HBV PCR testing of 681 syringes returned to the needle exchange program in New Haven, Connecticut, revealed a decline from 7.8% HBV-positive at the program's outset to 2.6%. HCV antibodies were found in 12.1% of 207 syringes tested.
Syringe testing can help estimate the prevalence and incidence of hepatitis virus infections when standard seroepidemiologic analyses cannot be applied.
Mots-clés Pascal : Virus hépatite C, Flaviviridae, Virus, Virus hépatite B, Hepadnaviridae, Réaction chaîne polymérase, Dépistage, Toxicomanie, Voie intraveineuse, Seringue, DNA, RNA, Anticorps, Programme sanitaire, Echange, Homme, Prévention
Mots-clés Pascal anglais : Hepatitis C virus, Flaviviridae, Virus, Hepatitis B virus, Hepadnaviridae, Polymerase chain reaction, Medical screening, Drug addiction, Intravenous administration, Syringe, DNA, RNA, Antibody, Sanitary program, Exchange, Human, Prevention
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0201877
Code Inist : 002B05C02G. Création : 199608.